DV
Dividend Vision

BRNS — Barinthus Biotherapeutics plc

Barinthus Biotherapeutics plc (BRNS)

Total return is -95.9% over the past 5.3 years, 195.2 points behind SPY at 99.3%. Its deepest 1-year drawdown was 65.9%.

Barinthus Biotherapeutics plc is a single-stock equity holding that trades as a public company rather than a traditional ETF with diversified holdings. The security does not currently pay distributions and operates without a stated expense ratio typical of fund structures. This holding primarily appeals to investors seeking exposure to a specific biotherapeutics company rather than those pursuing dividend income or broad portfolio diversification.

BRNS key facts

Asset type
Stock
Asset class
Equity
Inception date
05/03/2021
Distribution frequency
None
Last close
$0.59
Market cap
$24,141,696
Average volume
28600.0
Beta
-0.394
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.00